Loading...
•
Sep 30, 2022
Glaukos Q3 2022 Earnings Report
Glaukos' third quarter performance reflected commitment to advance key strategic priorities and execute plans amidst a dynamic macro environment.
Key Takeaways
Glaukos Corporation reported net sales of $71.3 million in Q3 2022, a 4.6% decrease compared to the same period in 2021. The company's gross margin was approximately 76%, and non-GAAP gross margin was approximately 84%.
Net sales of $71.3 million in Q3 2022.
Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022.
Gross margin of approximately 76% and non-GAAP gross margin of approximately 84% in Q3 2022.
Updated 2022 net sales guidance to $278 million to $280 million, compared to $275 million to $280 million previously.
Revenue by Segment
Forward Guidance
The company expects 2022 net sales to be in the range of $278 million to $280 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...